Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic fungal pneumonia occurring almost exclusively in immunocompromised hosts, characterized by subacute progressive dyspnea, non-productive cough, fever, and bilateral ground-glass infiltrates on imaging. [1-2] Mortality ranges from 10–20% in HIV-positive patients to 30–60% in non-HIV immunocompromised patients, where diagnosis is often delayed and presentation more fulminant. [3-4]
1. History
- Key HPI: Onset and tempo of dyspnea (subacute over days to weeks in HIV; more acute/fulminant in non-HIV), cough character (typically dry/non-productive), fever, chest discomfort [1][4]
- Timing: HIV patients — insidious over 1–4 weeks; non-HIV patients — rapid onset over days [3][5]
- Severity/progression: Exertional dyspnea progressing to resting dyspnea; worsening hypoxemia
- Associated symptoms: Night sweats, weight loss, fatigue, poor feeding (pediatric) [6]
- Important negatives: Absence of purulent sputum (productive cough suggests bacterial co-infection); absence of hemoptysis and pleuritic chest pain (atypical for PCP) [1]
2. Alarm Features
- Resting hypoxemia (SpO₂ <92%, PaO₂ <70 mmHg) or A-a gradient ≥35 mmHg — defines moderate-to-severe disease and triggers adjunctive corticosteroids [1][7]
- Spontaneous pneumothorax in an immunocompromised patient — highly suspicious for PCP [1]
- Rapid respiratory deterioration — especially in non-HIV patients, who can progress to ARDS quickly [3-4]
- Tachypnea >30/min, accessory muscle use, inability to speak in full sentences
- Clinical worsening after starting ART — consider immune reconstitution inflammatory syndrome (IRIS) [1]
3. Medications
Treatment
- TMP-SMX (first-line): TMP 15–20 mg/kg/day IV divided q6–8h for 21 days; transition to PO when improving in mild-moderate disease [1][7-8]
- Adjunctive corticosteroids for moderate-to-severe disease (PaO₂ <70 or A-a gradient ≥35): Prednisone 40 mg BID days 1–5 → 40 mg daily days 6–10 → 20 mg daily days 11–21 [1][7]
- Alternatives (for TMP-SMX intolerance):
- Mild-moderate: dapsone + TMP, atovaquone, or clindamycin + primaquine [1][6]
- Moderate-severe: IV pentamidine 4 mg/kg/day [6][9]
Prophylaxis
- TMP-SMX DS 1 tab daily or 1 tab 3×/week (preferred) [7][10-11]
- Alternatives: atovaquone 1500 mg PO daily, dapsone 100 mg PO daily, aerosolized pentamidine 300 mg monthly [9-10]
Contraindications/Cautions
- Check G6PD before dapsone or primaquine [1]
- Do NOT add leucovorin to TMP-SMX for PCP treatment — associated with higher failure rates [1]
- TMP-SMX permanently discontinued if Stevens-Johnson syndrome/TEN [1]
- Dose-adjust TMP-SMX for renal impairment [10][12]
- Monitor for hyperkalemia, myelosuppression, hepatotoxicity with TMP-SMX [10]
4. Diet
- Hydration: Maintain adequate IV hydration during TMP-SMX therapy to reduce nephrotoxicity risk
- Atovaquone must be taken with food — bioavailability increases ~3-fold with meals [6]
- No specific dietary triggers; nutritional supplementation recommended for malnourished patients [1]
5. Review of Systems
- Pulmonary: Dyspnea (exertional → resting), cough, chest tightness, pleurisy
- Constitutional: Fever, weight loss, night sweats, fatigue
- GI: Diarrhea, poor appetite (especially pediatric; also consider extrapulmonary PCP) [6]
- Neurologic/other organ systems: Rare extrapulmonary disease — eye, thyroid, spleen, GI tract, liver, bone marrow [6]
- Medication history: Current immunosuppressants, corticosteroid dose/duration, ART adherence, PCP prophylaxis use
6. Collateral History and Family History
- Collateral: HIV status and CD4 count, ART adherence, transplant history, chemotherapy regimen, immunosuppressive medications, prior PCP episodes, prophylaxis compliance
- Exposure history: Contact with known PCP cases (nosocomial clusters described among immunocompromised hosts) [2]
- Social context: Housing instability, substance use, barriers to medication adherence
- Family history: Primary immunodeficiency syndromes (rare)
7. Risk Factors
- HIV/AIDS with CD4 <200 cells/mm³ — ~90% of HIV-associated PCP occurs at this threshold [1]
- Corticosteroid use: ≥20 mg prednisone equivalent daily for ≥4 weeks [9-10][13]
- Hematologic malignancy (32% of modern non-HIV PCP cohorts), solid tumors on chemotherapy (22%), autoimmune diseases on immunosuppression (18%) [14]
- Solid organ or hematopoietic stem cell transplant — highest risk in first 6 months [9]
- Alemtuzumab, purine analogs (fludarabine, cladribine), temozolomide, CAR T-cell therapy [9-10]
- Lymphopenia (<0.7 × 10⁹/L) and combined corticosteroid + immunosuppressant use are independent risk factors in non-HIV patients [15]
- Cirrhosis — recently identified as carrying the highest adjusted mortality (OR 6.24) [14]
- Absence of prophylaxis — only 5.4% of patients in a large modern cohort were on prophylaxis at diagnosis [14]
8. Differential Diagnosis
- Bacterial pneumonia (community-acquired) — more acute, productive cough, lobar consolidation, elevated procalcitonin [1]
- Pulmonary tuberculosis — must always be considered in HIV; cavitary disease, upper lobe predominance, AFB smear [1]
- CMV pneumonitis — common co-pathogen in transplant recipients; similar ground-glass pattern [15]
- Pulmonary Kaposi sarcoma — nodular lesions, pleural effusions, endobronchial disease in HIV [1]
- Drug-induced pneumonitis (e.g., methotrexate, bleomycin) — temporal relationship with drug exposure
- Invasive pulmonary aspergillosis — neutropenic patients, nodules with halo sign, cavitation
- Viral pneumonia (influenza, SARS-CoV-2, RSV) — rapid antigen/PCR testing [1]
- Pulmonary edema/DAD — non-infectious mimics to consider [10]
Distinguishing features of PCP: Bilateral ground-glass opacities without effusion or cavitation, elevated LDH and β-D-glucan, subacute course, and low CD4 count [1][16]
9. Past Medical History
- HIV/AIDS: CD4 count nadir, viral load, ART regimen, prior opportunistic infections
- Prior PCP episode — high recurrence risk without secondary prophylaxis [17]
- Transplant history: Type, time since transplant, immunosuppressive regimen, CMV status
- Malignancy: Type, chemotherapy regimen, recent intensification
- Autoimmune disease: Granulomatosis with polyangiitis carries particularly high PCP risk [13]
- Chronic lung disease: Baseline pulmonary function
- Sulfa allergy history: Impacts treatment and prophylaxis options
10. Physical Exam
- Vital signs: Fever (present in most), tachypnea, tachycardia, hypoxemia (SpO₂ often <92% in moderate-severe disease) [1][6]
- Lung exam: Often normal at rest in mild disease; exertional exam may reveal diffuse dry "cellophane" rales. Bilateral basilar rales in more advanced disease [1][6]
- Absence of focal consolidation — diffuse process is typical
- Signs of respiratory distress: Accessory muscle use, nasal flaring, inability to speak in full sentences
- Oral exam: Oropharyngeal candidiasis (thrush) — suggests advanced immunosuppression and increases PCP suspicion [7]
- Skin: Kaposi sarcoma lesions, signs of other opportunistic infections
- Subcutaneous emphysema: May indicate pneumomediastinum/pneumothorax
11. Lab Studies
12. Imaging
- Chest X-ray (first-line): Bilateral, symmetrical ground-glass interstitial infiltrates in a perihilar "butterfly" pattern; may be normal in early/mild disease [1][20]
- CT chest without contrast (gold standard imaging): Diffuse or patchy ground-glass opacities; abnormal even when CXR is normal; a normal CT has high negative predictive value [1]
- Atypical findings: Cysts/blebs (risk for pneumothorax), nodules, upper-lobe predominance (associated with aerosolized pentamidine prophylaxis), pneumomediastinum [1][20]
- Findings suggesting alternative diagnosis: Cavitation, pleural effusion, focal lobar consolidation, intrathoracic adenopathy [1]
13. Special Tests
- Induced sputum with immunofluorescent staining: Sensitivity <50% to >90% depending on technique and lab experience [1]
- Bronchoscopy with BAL: Diagnostic procedure of choice; sensitivity 90–99% with DFA or PCR [1][7]
- Quantitative PCR (qPCR) on respiratory specimens: Increasingly replacing staining; high sensitivity but cannot reliably distinguish colonization from disease — higher organism loads favor true infection [1][21]
- Oral wash PCR + serum BDG combination: Emerging noninvasive strategy with excellent accuracy (97.9%) in non-HIV patients unable to undergo bronchoscopy [22]
- Methenamine silver (GMS) stain: Identifies cyst walls; classic cup-shaped organisms in foamy alveolar exudates [23]
- Direct immunofluorescence (DFA): Higher sensitivity than colorimetric stains (~95% on BAL) [1][7]
Key pearl: Treatment should NOT be delayed pending definitive diagnosis — organisms persist in specimens for days to weeks after starting therapy [1]
14. ECG
- Not a primary diagnostic tool for PCP
- Obtain ECG if using medications with cardiac effects: pentamidine (QT prolongation, torsades), ciprofloxacin (QTc prolongation) [1]
- Tachycardia is common and reflects hypoxemia/systemic illness
- Right heart strain pattern may be seen in severe cases with significant hypoxemia
15. Assessment
Severity stratification (guides treatment decisions): [1]
- Mild: PaO₂ ≥70 mmHg or A-a gradient <35 mmHg — can be treated outpatient with oral TMP-SMX
- Moderate: A-a gradient 35–45 mmHg — requires adjunctive corticosteroids
- Severe: A-a gradient ≥45 mmHg — IV therapy, adjunctive steroids, ICU consideration
Typical vs. atypical presentations: HIV patients present subacutely with high organism burden but lower inflammatory response; non-HIV patients present acutely with lower organism burden but more intense inflammation and higher mortality [3-5]
Complications: Respiratory failure/ARDS, pneumothorax, pneumomediastinum, IRIS (after ART initiation), treatment-related toxicity (myelosuppression, nephrotoxicity, hyperkalemia) [1][20]
16. Treatment Plan
Initial stabilization
- Supplemental O₂ to maintain SpO₂ >92%; early intubation if progressing to respiratory failure
- Start empiric TMP-SMX immediately if clinical suspicion is high — do not delay for diagnostic confirmation [1]
Definitive treatment (21-day course)
- TMP-SMX 15–20 mg/kg/day (TMP component) IV divided q6–8h; transition to PO when improving [1][7-8]
- Low-dose TMP-SMX (<12.5 mg/kg/day TMP) may have similar efficacy with fewer adverse events in non-HIV patients, though evidence is limited [24]
Adjunctive corticosteroids (moderate-to-severe, start within 72 hours): [1][7]
- Prednisone 40 mg PO BID × 5 days → 40 mg daily × 5 days → 20 mg daily × 11 days
- IV methylprednisolone at 80% of oral prednisone dose if unable to take PO
Alternative regimens (TMP-SMX intolerant): [1][6][9]
- Mild-moderate: Dapsone 100 mg PO daily + TMP 5 mg/kg PO TID; or atovaquone 750 mg PO BID with food; or clindamycin + primaquine
- Moderate-severe: IV pentamidine 4 mg/kg/day (monitor for hypoglycemia, pancreatitis, nephrotoxicity)
Immunosuppression management: Consider reduction in transplant recipients (with caution for IRIS risk) [2]
17. Disposition
Admission criteria
- PaO₂ <70 mmHg or A-a gradient ≥35 mmHg (moderate-to-severe disease)
- Inability to tolerate oral medications
- Significant comorbidities or hemodynamic instability
- Non-HIV immunocompromised patients (higher mortality, more fulminant course) [3-4]
ICU admission
- Respiratory failure requiring high-flow O₂, NIV, or mechanical ventilation
- A-a gradient ≥45 mmHg
- ICU mortality for PCP is 52% at 30 days and 67% at 90 days [25]
Outpatient treatment
Specialist consultation
- Infectious disease — all cases
- Pulmonology — for bronchoscopy/BAL if needed
- Critical care — for moderate-to-severe disease
18. Follow Up / Return Precautions
- Secondary prophylaxis: All patients who have had PCP must continue prophylaxis (TMP-SMX DS daily) until immune reconstitution — CD4 >200 cells/mm³ for >3 months on ART [7][17]
- Follow-up timing: Within 1 week of discharge; repeat imaging at 4–6 weeks if clinically indicated
- Expected recovery: Clinical improvement may take up to 1 week after starting therapy — early worsening does not necessarily indicate treatment failure [7]
- Return precautions — seek immediate care for:
- Worsening dyspnea or new chest pain (pneumothorax risk)
- Fever not improving after 5–7 days of therapy
- Rash, especially blistering or mucosal involvement (Stevens-Johnson syndrome)
- Signs of medication toxicity: jaundice, dark urine, easy bruising
- Treatment failure: If no improvement after 5–7 days of TMP-SMX, switch to IV pentamidine and pursue definitive diagnosis if not yet obtained [6]
- ART initiation: In newly diagnosed HIV, ART should be started within 2 weeks of PCP treatment initiation (balance benefit of immune reconstitution against IRIS risk) [1]
References
1. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
2. Pneumocystis Jiroveci. — Fishman JA. Seminars in Respiratory and Critical Care Medicine. 2020.
3. Prophylaxis for Pneumocystis Pneumonia (PCP) in Non-Hiv Immunocompromised Patients. — Stern A, Green H, Paul M, Vidal L, Leibovici L. The Cochrane Database of Systematic Reviews. 2014.
4. How to Diagnose and Treat a Patient Without Human Immunodeficiency Virus Infection Having Pneumocystis Jirovecii Pneumonia?. — Hänsel L, Schumacher J, Denis B, et al. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2023.
5. Opinions on Pneumocystis jirovecii prophylaxis in autoimmune neuromuscular disorders. — Claytor B, Li Y. Muscle & Nerve. 2022.
6. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
7. Fungal Infections in HIV/AIDS. — Limper AH, Adenis A, Le T, Harrison TS. The Lancet. Infectious Diseases. 2017.
8. FDA Drug Label. — Updated date: 2024-12-30. Food and Drug Administration.
9. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. — Fishman JA, Gans H, AST Infectious Diseases Community of Practice. Clinical Transplantation. 2019.
10. Prevention and Treatment of Cancer-Related Infections. — Updated 2026-03-11. National Comprehensive Cancer Network.
11. HIV Infection — Screening, Diagnosis, and Treatment. — Saag MS. The New England Journal of Medicine. 2021.
12. Population Pharmacokinetics and Monte Carlo-Based Dosing Optimization of Trimethoprim-Sulfamethoxazole. — Chen B, Chen Y, Chen M, et al. Antimicrobial Agents and Chemotherapy. 2025.
13. Risk Factors and Prevention of Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases. — Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D. Chest. 2020.
14. An Observational Analysis of a Large Cohort of Pneumocystis Jirovecii Pneumonia. — Pulsipher AM, Vikram HR, Gotway MB, et al. Open Forum Infectious Diseases. 2025.
15. Risk Factors Associated With Pneumocystis Jirovecii Pneumonia in Non-Hiv Immunocompromised Patients and Co-Pathogens Analysis by Metagenomic Next-Generation Sequencing. — Huang L, Xu S, Huang Z, et al. BMC Pulmonary Medicine. 2023.
16. A Retrospective Comparative Study: How to Distinguish Pneumocystis Jirovecii Pneumonia From Other Pneumonias in Kidney Transplant Recipients?. — Hu M, Chen H, Chen R, et al. Diagnostic Microbiology and Infectious Disease. 2026.
17. Pneumocystis Pneumonia. — Thomas CF, Limper AH. The New England Journal of Medicine. 2004.
18. Diagnostic Accuracy of the 1,3-Beta-D-Glucan Test and Lactate Dehydrogenase for Pneumocystis Pneumonia in Non-Hiv Patients. — Sun R, Lv D, Xiao M, et al. Scientific Reports. 2021.
19. Diagnostic Test Accuracy of the Fungitell Serum (1→3)-Β-D-Glucan Assay for the Diagnosis of Pneumocystis Jirovecii Pneumonia: A Systematic Review and Meta-Analysis. — Prosty C, Luo OD, Khalaf R, et al. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2025.
20. Clinical Characteristics and Outcomes of Severe Non‐HIV Related Pneumocystis jirovecii Pneumonia in the Pediatric Intensive Care Unit. — An K, Han Y, Luo C, Hu W, Qian J. Pediatric Pulmonology. 2025.
21. Diagnostic Tests Performance in Detecting Pneumocystis Jirovecii: A Systematic Review and Meta-Analysis. — Zhang L, Zheng C, Sun Y, et al. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2025.
22. Combined Serum (1,3)-Β-D-Glucan and Oral Wash PCR as a Noninvasive Diagnostic Strategy for Early Detection of Pneumocystis Jirovecii Pneumonia: An Observational Retrospective Study. — Falcó-Roget A, Albasanz-Puig A, Pérez-González A, et al. Open Forum Infectious Diseases. 2026.
23. Molecular diagnostics of infectious disease: Detection and characterization of microbial agents in cytology samples. — Caruso CR, Yang Z. Diagnostic Cytopathology. 2023.
24. Low-Dose Vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia In Non-Hiv-Infected Patients: A Multicenter, Retrospective Observational Cohort Study. — Nagai T, Matsui H, Fujioka H, et al. Chest. 2023.
25. Pneumocystis Jirovecii Pneumonia in Intensive Care Units: A Multicenter Study by ESGCIP and EFISG. — Giacobbe DR, Dettori S, Di Pilato V, et al. Critical Care. 2023.